ENTX vs. CRBU, CADL, IPSC, MGX, ZURA, ELEV, IPHA, IVVD, CHRS, and GLUE
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Caribou Biosciences (CRBU), Candel Therapeutics (CADL), Century Therapeutics (IPSC), Metagenomi (MGX), Zura Bio (ZURA), Elevation Oncology (ELEV), Innate Pharma (IPHA), Invivyd (IVVD), Coherus BioSciences (CHRS), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "biological products, except diagnostic" industry.
Caribou Biosciences (NASDAQ:CRBU) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
In the previous week, Entera Bio had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Entera Bio and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.78 beat Entera Bio's score of 0.62 indicating that Entera Bio is being referred to more favorably in the news media.
Entera Bio received 157 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 66.92% of users gave Entera Bio an outperform vote while only 53.13% of users gave Caribou Biosciences an outperform vote.
77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 8.9% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Entera Bio has lower revenue, but higher earnings than Caribou Biosciences. Entera Bio is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Caribou Biosciences has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
Caribou Biosciences currently has a consensus target price of $21.50, suggesting a potential upside of 646.53%. Entera Bio has a consensus target price of $10.00, suggesting a potential upside of 344.44%. Given Entera Bio's higher probable upside, research analysts clearly believe Caribou Biosciences is more favorable than Entera Bio.
Entera Bio has a net margin of 0.00% compared to Entera Bio's net margin of -345.05%. Entera Bio's return on equity of -33.42% beat Caribou Biosciences' return on equity.
Summary
Caribou Biosciences beats Entera Bio on 9 of the 17 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entera Bio Competitors List
Related Companies and Tools
